請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68928
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王淑慧 | |
dc.contributor.author | Cheng-Hua Hsieh | en |
dc.contributor.author | 謝政樺 | zh_TW |
dc.date.accessioned | 2021-06-17T02:42:35Z | - |
dc.date.available | 2022-09-14 | |
dc.date.copyright | 2017-09-14 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-16 | |
dc.identifier.citation | 1. Li, X., et al., Atherosclerotic coronary artery disease: The accuracy of measures to diagnose preclinical atherosclerosis. Exp Ther Med, 2016. 12(5): p. 2899-2902.
2. Roger, V.L., et al., Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation, 2012. 125(1): p. e2-e220. 3. Lagerqvist, B., et al., Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med, 2007. 356(10): p. 1009-19. 4. Bazzoni, G. and E. Dejana, Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev, 2004. 84(3): p. 869-901. 5. Andersson, K.E. and K. Persson, The L-arginine/nitric oxide pathway and non-adrenergic, non-cholinergic relaxation of the lower urinary tract. Gen Pharmacol, 1993. 24(4): p. 833-9. 6. Majesky, M.W., et al., The adventitia: a dynamic interface containing resident progenitor cells. Arterioscler Thromb Vasc Biol, 2011. 31(7): p. 1530-9. 7. Celermajer, D.S., et al., Noninvasive Detection of Endothelial Dysfunction in Children and Adults at Risk of Atherosclerosis. Lancet, 1992. 340(8828): p. 1111-1115. 8. Giannattasio, C., et al., Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia. Atherosclerosis, 1996. 124(2): p. 249-60. 9. Huang, Z.S., et al., In hypercholesterolemia, lower peripheral monocyte count is unique among the major predictors of atherosclerosis. Arterioscler Thromb Vasc Biol, 1996. 16(2): p. 256-61. 10. Stein, P.D. and H.N. Sabbah, Measured turbulence and its effect on thrombus formation. Circ Res, 1974. 35(4): p. 608-14. 11. Yao, Z., Frontiers in atherosclerosis, heart disease and diabetes. Cardiovasc Hematol Disord Drug Targets, 2014. 14(2): p. 87-8. 12. Yla-Herttuala, S., et al., Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest, 1989. 84(4): p. 1086-95. 13. Quinn, M.T., et al., Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A, 1987. 84(9): p. 2995-8. 14. Griffith, R.L., et al., Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med, 1988. 168(3): p. 1041-59. 15. Strauss, B.H., et al., Extracellular-Matrix Remodeling after Balloon Angioplasty Injury in a Rabbit Model of Restenosis. Circulation Research, 1994. 75(4): p. 650-658. 16. Ross, R., et al., Localization of Pdgf-B Protein in Macrophages in All Phases of Atherogenesis. Science, 1990. 248(4958): p. 1009-1012. 17. Handa, N., et al., Ischemic stroke events and carotid atherosclerosis. Results of the Osaka Follow-up Study for Ultrasonographic Assessment of Carotid Atherosclerosis (the OSACA Study). Stroke, 1995. 26(10): p. 1781-6. 18. Pedersen, T.R., et al., Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl, 2004. 5(3): p. 81-7. 19. Stenvinkel, P., et al., Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney International, 1999. 55(5): p. 1899-1911. 20. Serruys, P.W., et al., A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary-Artery Disease. New England Journal of Medicine, 1994. 331(8): p. 489-495. 21. Bauters, C., et al., Predictors of restenosis after coronary stent implantation. Journal of the American College of Cardiology, 1998. 31(6): p. 1291-1298. 22. Kornowski, R., et al., In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol, 1998. 31(1): p. 224-30. 23. Schwartz, R.S., D.R. Holmes, and E.J. Topol, The Restenosis Paradigm Revisited - an Alternative Proposal for Cellular Mechanisms. Journal of the American College of Cardiology, 1992. 20(5): p. 1284-1293. 24. Owens, G.K., M.S. Kumar, and B.R. Wamhoff, Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiological Reviews, 2004. 84(3): p. 767-801. 25. Scott, N.A., Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev, 2006. 58(3): p. 358-76. 26. Welt, F.G. and C. Rogers, Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol, 2002. 22(11): p. 1769-76. 27. Strauss, B.H., et al., Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res, 1994. 75(4): p. 650-8. 28. Chang, M.W., et al., Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest, 1995. 96(5): p. 2260-8. 29. Rensen, S.S., P.A. Doevendans, and G.J. van Eys, Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J, 2007. 15(3): p. 100-8. 30. Oguchi, S., et al., Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. Arterioscler Thromb Vasc Biol, 2000. 20(7): p. 1729-36. 31. Rogers, C., E.R. Edelman, and D.I. Simon, A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A, 1998. 95(17): p. 10134-9. 32. Zeiffer, U., et al., Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. Circ Res, 2004. 94(6): p. 776-84. 33. Moiseeva, E.P., Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc Res, 2001. 52(3): p. 372-86. 34. Thyberg, J., Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Histol Histopathol, 1998. 13(3): p. 871-91. 35. Peppel, K., et al., Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms. Cardiovasc Res, 2005. 65(3): p. 674-82. 36. Doran, A.C., N. Meller, and C.A. McNamara, Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol, 2008. 28(5): p. 812-9. 37. Sousa, J.E., et al., Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation, 2001. 104(17): p. 2007-11. 38. Degertekin, M., et al., Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation, 2002. 106(13): p. 1610-3. 39. Sarbassov, D.D., et al., Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol, 2004. 14(14): p. 1296-302. 40. Sabers, C.J., et al., Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem, 1995. 270(2): p. 815-22. 41. Dangas, G.D., et al., In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol, 2010. 56(23): p. 1897-907. 42. Finn, A.V., et al., Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 2007. 115(18): p. 2435-41. 43. de Man, F.H., et al., Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Neth Heart J, 2007. 15(11): p. 382-6. 44. Finn, A.V., et al., Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation, 2005. 112(2): p. 270-8. 45. Cook, S., et al., Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation, 2007. 115(18): p. 2426-34. 46. Hofma, S.H., et al., Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J, 2006. 27(2): p. 166-70. 47. Meier, P., et al., Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol, 2007. 49(1): p. 15-20. 48. Joner, M., et al., Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 2006. 48(1): p. 193-202. 49. Nakazawa, G., et al., Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation, 2008. 118(11): p. 1138-45. 50. Finn, A.V., G. Nakazawa, and R. Virmani, Pathology of drug-eluting stents: implications for coronary intervention. Indian Heart J, 2007. 59(2 Suppl B): p. B41-9. 51. Barilli, A., et al., In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res, 2008. 78(3): p. 563-71. 52. Demidenko, Z.N., et al., Rapamycin decelerates cellular senescence. Cell Cycle, 2009. 8(12): p. 1888-95. 53. Hayashi, S., et al., The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol, 2009. 175(5): p. 2226-34. 54. Habib, A., et al., Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-alpha activation and disruption of the p120-vascular endothelial cadherin interaction. Arterioscler Thromb Vasc Biol, 2013. 33(10): p. 2425-31. 55. Liu, H.T., et al., Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells. Tex Heart Inst J, 2010. 37(2): p. 194-201. 56. Fukuda, D., et al., Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol, 2009. 612(1-3): p. 87-92. 57. Jabs, A., et al., Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. J Am Coll Cardiol, 2008. 51(22): p. 2130-8. 58. Jeanmart, H., et al., Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant, 2002. 21(9): p. 990-8. 59. Dimmeler, S. and A.M. Zeiher, Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? J Mol Med (Berl), 2004. 82(10): p. 671-7. 60. Aoki, J., et al., Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol, 2005. 45(10): p. 1574-9. 61. Peichev, M., et al., Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood, 2000. 95(3): p. 952-8. 62. Anjos-Afonso, F. and D. Bonnet, Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood, 2007. 109(3): p. 1298-306. 63. Werner, N., et al., Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol, 2002. 22(10): p. 1567-72. 64. Walter, D.H., et al., Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation, 2002. 105(25): p. 3017-24. 65. Tanous, D., et al., Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. Atherosclerosis, 2006. 189(2): p. 342-9. 66. Hayashi, K., et al., In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther, 2000. 7(19): p. 1664-71. 67. Hayflick, L. and P.S. Moorhead, The serial cultivation of human diploid cell strains. Exp Cell Res, 1961. 25: p. 585-621. 68. Campisi, J., Replicative senescence: an old lives' tale? Cell, 1996. 84(4): p. 497-500. 69. Greider, C.W., Telomeres and senescence: the history, the experiment, the future. Curr Biol, 1998. 8(5): p. R178-81. 70. Dimri, G.P., et al., A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A, 1995. 92(20): p. 9363-7. 71. Vasile, E., et al., Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J, 2001. 15(2): p. 458-66. 72. Fenton, M., et al., Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries. Arterioscler Thromb Vasc Biol, 2001. 21(2): p. 220-6. 73. Westphal, C.H., M.A. Dipp, and L. Guarente, A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci, 2007. 32(12): p. 555-60. 74. Derbyshire, M.K., K.G. Weinstock, and J.N. Strathern, HST1, a new member of the SIR2 family of genes. Yeast, 1996. 12(7): p. 631-40. 75. Langley, E., et al., Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J, 2002. 21(10): p. 2383-96. 76. Potente, M., et al., SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev, 2007. 21(20): p. 2644-58. 77. Ota, H., et al., Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol, 2007. 43(5): p. 571-9. 78. Potente, M. and S. Dimmeler, Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle, 2008. 7(14): p. 2117-22. 79. Zu, Y., et al., SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res, 2010. 106(8): p. 1384-93. 80. Menghini, R., et al., MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation, 2009. 120(15): p. 1524-32. 81. Ota, H., et al., Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol, 2008. 28(9): p. 1634-9. 82. Ota, H., et al., Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol, 2010. 30(11): p. 2205-11. 83. Hong, S., et al., Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation. J Biol Chem, 2014. 289(19): p. 13132-41. 84. Forstermann, U., et al., Nitric-Oxide Synthase Isozymes - Characterization, Purification, Molecular-Cloning, and Functions. Hypertension, 1994. 23(6): p. 1121-1131. 85. GarciaCardena, G., et al., Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. Journal of Biological Chemistry, 1996. 271(44): p. 27237-27240. 86. Fulton, D., et al., Agonist-stimulated endothelial nitric oxide synthase activation and vascular relaxation - Role of eNOS phosphorylation at Tyr83. Circulation Research, 2008. 102(4): p. 497-504. 87. Ayajiki, K., et al., Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circulation Research, 1996. 78(5): p. 750-758. 88. Lahteenvuo, J. and A. Rosenzweig, Effects of Aging on Angiogenesis. Circulation Research, 2012. 110(9): p. 1252-1263. 89. Laufs, U., et al., Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998. 97(12): p. 1129-1135. 90. Vonderleyen, H.E., et al., Gene-Therapy Inhibiting Neointimal Vascular Lesion - in-Vivo Transfer of Endothelial-Cell Nitric-Oxide Synthase Gene. Proceedings of the National Academy of Sciences of the United States of America, 1995. 92(4): p. 1137-1141. 91. Varenne, O., et al., Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation, 1998. 98(9): p. 919-926. 92. Sharif, F., et al., Gene-eluting stents: Adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Molecular Therapy, 2008. 16(10): p. 1674-1680. 93. Hambrecht, R., et al., Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation, 2003. 107(25): p. 3152-3158. 94. Stocker, R. and J.F. Keaney, Jr., Role of oxidative modifications in atherosclerosis. Physiol Rev, 2004. 84(4): p. 1381-478. 95. Gomez, C., et al., Oxidative stress induces early-onset apoptosis of vascular smooth muscle cells and neointima formation in response to injury. Biosci Rep, 2015. 35(4). 96. Liu, S.L., et al., Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice. Cardiovasc Res, 2009. 82(1): p. 161-9. 97. Kim, J.Y., et al., Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia. Cardiovasc Res, 2009. 82(3): p. 550-60. 98. Qin, Z.X., et al., Hydrogen-rich saline prevents neointima formation after carotid balloon injury by suppressing ROS and the TNF-alpha/NF-kappa B pathway. Atherosclerosis, 2012. 220(2): p. 343-350. 99. Tombran-Tink, J., G.G. Chader, and L.V. Johnson, PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res, 1991. 53(3): p. 411-4. 100. Steele, F.R., et al., Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A, 1993. 90(4): p. 1526-30. 101. Bhutto, I.A., et al., Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res, 2006. 82(1): p. 99-110. 102. Dawson, D.W., et al., Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science, 1999. 285(5425): p. 245-8. 103. Ek, E.T., C.R. Dass, and P.F. Choong, PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med, 2006. 12(10): p. 497-502. 104. Wang, M., et al., Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes. Am J Physiol Endocrinol Metab, 2009. 297(6): p. E1378-87. 105. Chung, C., et al., Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol, 2008. 48(3): p. 471-8. 106. Yamagishi, S., et al., Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res, 2005. 320(3): p. 437-45. 107. Yamagishi, S., et al., Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol, 2004. 37(2): p. 497-506. 108. Inagaki, Y., et al., Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia, 2003. 46(2): p. 284-7. 109. Zamiri, P., et al., Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci, 2006. 47(9): p. 3912-8. 110. Yamagishi, S., et al., Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev, 2009. 25(3): p. 266-71. 111. Takenaka, K., et al., Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis, 2008. 197(1): p. 25-33. 112. Wang, S.H., et al., Pigment epithelium-derived factor reduces the PDGF-induced migration and proliferation of human aortic smooth muscle cells through PPAR gamma activation. International Journal of Biochemistry & Cell Biology, 2012. 44(2): p. 280-289. 113. Nakamura, K., et al., Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. American Journal of Pathology, 2007. 170(6): p. 2159-2170. 114. Sata, M., et al., A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. Journal of Molecular and Cellular Cardiology, 2000. 32(11): p. 2097-2104. 115. Fukuda, D., et al., Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation, 2005. 111(7): p. 926-931. 116. Erusalimsky, J.D., Vascular endothelial senescence: from mechanisms to pathophysiology. J Appl Physiol (1985), 2009. 106(1): p. 326-32. 117. Scotland, R.S., et al., Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circulation Research, 2002. 90(8): p. 904-910. 118. Nakazawa, G., et al., Anti-CD34 Antibodies Immobilized on the Surface of Sirolimus-Eluting Stents Enhance Stent Endothelialization. Jacc-Cardiovascular Interventions, 2010. 3(1): p. 68-75. 119. Navab, M., et al., Monocyte adhesion and transmigration in atherosclerosis. Coron Artery Dis, 1994. 5(3): p. 198-204. 120. Zollner, S., et al., Changes of endothelial nitric oxide synthase level and activity during endothelial cell proliferation. Endothelium, 2000. 7(3): p. 169-84. 121. Chavakis, E., et al., Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation, 2001. 103(16): p. 2102-2107. 122. Murohara, T., et al., Role of endothelial nitric oxide synthase in endothelial cell migration. Arteriosclerosis Thrombosis and Vascular Biology, 1999. 19(5): p. 1156-1161. 123. Erdogdu, O., et al., Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS- and PI3K/Akt-dependent pathways but independently of GLP-1 receptor. Diabetologia, 2009. 52: p. S109-S109. 124. Gentile, C., R.C. Muise-Helmericks, and C.J. Drake, VEGF-mediated phosphorylation of eNOS regulates angioblast and embryonic endothelial cell proliferation. Developmental Biology, 2013. 373(1): p. 163-175. 125. Parenti, A., et al., The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. Faseb Journal, 2001. 15(6): p. 1487-+. 126. Tilling, L., P. Chowienczyk, and B. Clapp, Progenitors in motion: mechanisms of mobilization of endothelial progenitor cells. Br J Clin Pharmacol, 2009. 68(4): p. 484-92. 127. Cho, H.J., et al., Mobilized endothelial progenitor cells accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation, 2003. 108(17): p. 354-354. 128. Szmitko, P.E., et al., Endothelial progenitor cells - New hope for a broken heart. Circulation, 2003. 107(24): p. 3093-3100. 129. Lapidot, T. and I. Petit, Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Experimental Hematology, 2002. 30(9): p. 973-981. 130. Wright, D.E., et al., Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. Journal of Experimental Medicine, 2002. 195(9): p. 1145-1154. 131. Sweeney, E.A., et al., Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood, 2002. 99(1): p. 44-51. 132. Zheng, H., et al., Migration of endothelial progenitor cells mediated by stromal cell-derived Factor-1 alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. Journal of Cardiovascular Pharmacology, 2007. 50(3): p. 274-280. 133. Hiasa, K., et al., Gene transfer of stromal cell-derived factor-1 alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway - Next-generation chemokine therapy for therapeutic neovascularization. Circulation, 2004. 109(20): p. 2454-2461. 134. Zhou, J.L., et al., Rosuvastatin Enhances Angiogenesis via eNOS-Dependent Mobilization of Endothelial Progenitor Cells. Plos One, 2013. 8(5). 135. Dimmeler, S., et al., HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. Journal of Clinical Investigation, 2001. 108(3): p. 391-397. 136. Matter, C.M., et al., Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. Journal of Cardiovascular Pharmacology, 2006. 48(6): p. 286-292. 137. Babinska, A., et al., Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrology Dialysis Transplantation, 1998. 13(12): p. 3153-3159. 138. Camici, G.G., et al., Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. European Heart Journal, 2010. 31(2): p. 236-242. 139. Yamagishi, S.I., et al., Pigment epithelium-derived factor (PEDF) inhibits collagen-induced platelet activation by reducing intraplatelet nitrotyrosine levels. International Journal of Cardiology, 2010. 140(1): p. 121-122. 140. Takenaka, K., et al., Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis, 2008. 197(1): p. 25-33. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68928 | - |
dc.description.abstract | 藥物釋放型支架(Drug eluting stent)是目前用來治療因動脈粥狀硬化導致血管阻塞的主要方式,藥物可藉由抑制血管中層平滑肌細胞移行增生的特性達到抗血管內膜增生(Neointima hyperplasia),而此技術已應用在超過百萬名心血管疾病患者中。但近年來,許多臨床報告指出藥物釋放型支架會嚴重地延緩病人血管再內皮化(Re-endothelialization)及影響內皮正常功能,造成病患在晚期有血栓形成、支架再狹窄、血管功能喪失等等併發症,甚至存在較高的死亡率。因此,抑制血管內膜增生及加速血管再內皮化是目前發展藥物釋放型支架的新方針。色素上皮衍生因子(Pigment epithelium-derived factor , PEDF)為多功能性的分泌型蛋白質,在心血管疾病方面已被證實具有抗發炎、抗氧化及抗平滑肌增生的功用,因此本實驗目的是探討PEDF是否能成為發展藥物釋放型支架的新方向。在體外實驗,我們利用人類臍帶靜脈內皮細胞及臍帶間質內皮前驅細胞作為探討血管再內皮化的機制;大鼠主動脈平滑肌細胞及巨噬細胞RAW264.7則用來進行抗增生、抗發炎試驗。體內實驗則利用血管內皮損傷模式觀察血管再內皮化及血管內膜增生。本篇實驗中另加入臨床用藥Sirolimus作為比較組。初步實驗結果顯示,在血管內皮研究中,PEDF能有效增加內皮細胞增生移行、誘導內皮前驅細胞產生趨化性及貼附能力,並於動物實驗中觀察到PEDF促使內皮前驅細胞釋放和加速血管再內皮化。另在血管內膜增生相關實驗顯示PEDF能藉由抗細胞增生及抗發炎特性達到抑制血管內膜增生,同時PEDF也具抗血管氧化壓力能力。而Sirolimus同樣地具有抗血管內膜增生能力,但會導致血管氧化壓力上升、延緩血管再內皮化、抑制內皮細胞功能。總結本篇實驗,PEDF具有抑制血管內膜增生、加速血管再內皮化和促進血管細胞功能的特性,期望未來能成為新的潛力藥物。 | zh_TW |
dc.description.abstract | Drug-euting stents (DES) are the devices developed for preventing SMC proliferation-mediated restenosis and have been used in millions of patients with Coronary artery disease (CHD). However, in recent year, clinical reports reveal that DES severely impair endothelial functions and delay re-endothelialization. These cause the increased risk of in-stent restenosis, late thrombosis and even mortality in patients. Pigment epithelium-derived factor (PEDF), a cytokine which isolate from retina pigment epithelial cells, has the multiple functions of potential neuronal differentiating activity, anti-inflammation, and smooth muscle growth inhibition. The aim of the study is to investigate whether PEDF has beneficial effects in vascular system and thus may be a new strategy in developing DES. In vitro, we use Human Umbilical Vein Endothelial Cell (HUVEC) and Endothelial Precursor Cell (EPC), which are important roles in endothelial recoverage, as part of cell models; Using Rat Aortic Smooth Muscle Cell (RASMC) and RAW264.7 cell as another part studies proliferation and inflammation. Under different condition, cells are individually treated with PEDF and Sirolimus, a drug widely used in DES, as a comparison. In vivo, we use wire injury model in C57/B6 mice to study the effect of re-endothelialization within Saline, PEDF and Sirolimus group. The preliminary data shows that PEDF effectively enhances cell growth, migration and homeostasis in HUVEC as well as increasing the capacity of migration and adhesion in EPC. In vitro, day 5 after injury, PEDF significantly increases CD133, CD34 and SSEA-1 positive cell in peripheral blood cell, which suggests that PEDF mobilizes endothelial progenitor cells from bone marrow; Day 7 after injury, PEDF group has nearly achieved complete re-endothelialization and further shows the lower oxidative stress compared to saline group at day 28 after injury. Moreover, PEDF has the well-known capability to inhibit the proliferation of SMC and inflammation in both SMC and RAW264.7 cell. Instead, Sirolimus not only triggers the inhibition of endothelial normal functions but abnormal increment of cell senescence in cell model. Sirolimus treated mice also have the highest level of oxidative stress in injuryed artery. In conclusion, via accelerated re-endothelialization and protection of vascular cells, PEDF may have the potential to prevent in-stent restenosis and be a new trend in developing DES. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T02:42:35Z (GMT). No. of bitstreams: 1 ntu-106-R04446007-1.pdf: 3156013 bytes, checksum: 01c65da5215d9890f36b98da25186f31 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 目錄
Abstract I 摘要 III 縮寫表 IV 目錄 V 壹、 緒論 1 一、 前言 1 二、 動脈結構 1 三、 動脈粥狀硬化與血管栓塞 2 四、 支架再狹窄的起因 3 五、 平滑肌細胞與支架再狹窄的關係 3 六、 藥物釋放型支架的發展 4 七、 內皮細胞及內皮前驅細胞與血管再內皮化的關係 5 八、 內皮細胞老化及其分子機制 6 九、 eNOS與心血管疾病的關聯 6 十、 氧化壓力與心血管疾病的關聯 7 十一、 PEDF與心血管疾病的關聯 8 十二、 研究動機和實驗設計 9 貳、 實驗材料 10 一、 儀器設備 10 二、 實驗材料 10 細胞培養 10 結晶紫染色 11 西方墨點法 11 β-半乳糖苷酶染色法 12 細胞移行 12 流式細胞儀 12 一氧化氮檢測 13 動物實驗 13 免疫組織染色法 13 三、 溶液配置 13 參、 實驗方法 16 一、 細胞實驗 16 人類臍帶靜脈內皮細胞(HUVECs)之初級培養 16 人類臍帶間質內皮前驅細胞(EPCs)之初級培養 16 細胞株之培養 17 結晶紫染色分析 17 細胞傷口癒合分析 18 β-半乳糖苷酶染色法 18 西方墨點法 19 細胞穿膜實驗 20 細胞貼附支架實驗 20 單核球黏附實驗 20 一氧化氮試驗分析 21 流式細胞儀分析 21 二、 動物實驗 22 動物股動脈去內皮傷害模式 22 流式細胞儀分析 23 伊文斯蘭(Evans blue)染色 23 免疫組織化學染色 24 Weigert's resorcin fuchsin stain 24 二氫乙啶(DHE)染色 25 數據統計分析 25 肆、 實驗結果 26 一、 PEDF對於內皮細胞增生的作用 26 二、 PEDF對於內皮細胞移行的作用 26 三、 PEDF對於內皮細胞老化的影響及分子機制探討 26 四、 PEDF對於內皮細胞內eNOS磷酸化的作用 27 五、 PEDF對於EPCs趨化性的作用 27 六、 PEDF對於EPCs貼附能力的作用 28 七、 PEDF對於EPCs從骨髓釋放的作用 28 八、 PEDF對於血管再內皮化的作用 29 九、 PEDF對於RASMC發炎及單核球黏附的影響 29 十、 PEDF對於巨噬細胞RAW264.7發炎及NO釋放的影響 30 十一、 PEDF對於RASMC增生的影響 30 十二、 PEDF對於血管內膜增生的影響 31 十三、 PEDF對於血管損傷後氧化壓力的影響 31 十四、 PEDF對於血管內膜長期增生的影響 32 伍、 討論 33 陸、 附圖 37 圖一、 PEDF對於內皮細胞增生的作用 37 圖二、 PEDF對於內皮細胞移行的作用 38 圖三、 PEDF對於內皮細胞老化的影響及分子機制探討 39 圖四、 PEDF對於內皮細胞內eNOS磷酸化的作用 41 圖五、 PEDF對於EPCs趨化性的作用 42 圖六、 PEDF對於EPCs貼附能力的作用 43 圖七、 PEDF對於EPCs從骨髓釋放的作用 44 圖八、 PEDF對於血管再內皮化的作用 45 圖九、 PEDF對於RASMC發炎及單核球黏附的影響 46 圖十、 PEDF對於巨噬細胞RAW264.7發炎及NO釋放的影響 47 圖十一、 PEDF對於RASMC增生的影響 48 圖十二、 PEDF對於血管內膜增生的影響 49 圖十三、 PEDF對於血管損傷後氧化壓力的影響 50 圖十四、 PEDF對於血管內膜長期增生的影響 51 柒、 參考文獻 52 | |
dc.language.iso | zh-TW | |
dc.title | PEDF在血管再狹窄化的治療效果及相關機制 | zh_TW |
dc.title | The therapeutic effects and the relative mechanisms of pigment epithelium-derived factor on restenosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林豐彥,王仰高,陳金銓,龔秀妮 | |
dc.subject.keyword | 藥物釋放型支架,支架再狹窄化,血管再內皮化,血管內膜增生,色素上皮衍生因子, | zh_TW |
dc.subject.keyword | in-stent restenosis,drug eluting stent,re-endothelialization,neointima hyperplasia,pigment epithelial derived factor, | en |
dc.relation.page | 62 | |
dc.identifier.doi | 10.6342/NTU201703698 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學暨細胞生物學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 3.08 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。